Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof

A method of targeting cells expressing EGFR in a subject, comprising administering to the subject a composition comprising an ABM that specifically binds EGFR and a pharmaceutically acceptable carrier;

• wherein the ABM comprises a heavy chain variable domain and a light chain variable domain;
• wherein the heavy chain variable domain comprises:
• (a) a CDR1 selected from the group consisting of:
• SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:123, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, and SEQ ID NO:125,
• (b) a CDR2 selected from the group consisting of:
• SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:127, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:101, SEQ ID NO:103, and SEQ ID NO:105, and
• (c) the CDR3 of SEQ ID NO:107;
• and
• wherein the light chain variable domain comprises:
• (a) the CDR1 of SEQ ID NO:113,
• (b) the CDR2 of SEQ ID NO:115, and
• (c) the CDR3 of SEQ ID NO:117.

A method of targeting cells expressing EGFR in a subject, comprising administering to the subject a composition comprising an ABM that specifically binds EGFR and a pharmaceutically acceptable carrier;

• wherein the ABM comprises:
• (a) a heavy chain variable domain comprising a sequence selected from the group consisting of:
• SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, and SEQ ID NO:121;
• and
• (b)(1) a light chain variable domain comprising a sequence selected from the group consisting of:
• SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:49, and SEQ ID NO:51, or
• (b)(2) a light chain variable domain comprising the sequence of SEQ ID NO:45 having an amino acid substitution selected from the group consisting of:
• N30R, Y32W, N34G, N50T, T51A, N52S, N53S, T56S, and F94Y.

A method of targeting cells expressing EGFR in a subject, comprising administering to the subject a composition comprising an ABM that specifically binds EGFR and a pharmaceutically acceptable carrier;

• wherein the ABM comprises:
• (a) a heavy chain variable domain comprising a sequence selected from the group consisting of:
• SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, and SEQ ID NO:121;
• and
• (b)(1) a light chain variable domain comprising a sequence selected from the group consisting of:
• SEQ ID NO:45, SEQ ID NO:49, and SEQ ID NO:51, or
• (b)(2) a light chain variable domain comprising the sequence of SEQ ID NO:45 having an amino acid substitution selected from the group consisting of:
• N30R, Y32W, N34G, N50T, T51A, N52S, N53S, T56S, and F94Y.